Ascendis Pharma A/S (ASND) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Hellerup, Denmark. 현재 CEO는 Jan Moller Mikkelsen.
ASND 을(를) 보유 IPO 날짜 2015-01-28, 1,017 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $15.34B.
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Hellerup, Denmark, dedicated to developing innovative therapeutics for unmet medical needs. The company's commercial product, SKYTROFA, treats growth hormone deficiency in patients, while its robust pipeline includes TransCon-based therapies targeting pediatric and adult growth hormone deficiency, hypoparathyroidism, achondroplasia, and various oncology indications. Founded in 2006, Ascendis leverages its proprietary TransCon technology platform to extend the duration and improve the efficacy of therapeutic proteins across multiple disease areas.
